M Di Simplicio1, R Norbury2, A Reinecke2, C J Harmer2. 1. MRC Brain and Cognition Sciences Unit, Cambridge, UK. 2. University Department of Psychiatry, Warneford Hospital, Oxford, UK.
Abstract
BACKGROUND: Short-term antidepressant administration has been reported to decrease amygdala response to threat in healthy volunteers and depressed patients. Neuroticism (N) is a risk factor for depression but has also been associated with slow or incomplete remission with antidepressant drug treatment. Our aim was to investigate early selective serotonin reuptake inhibitor (SSRI) administration neural effects on implicit processing of fearful facial expressions in volunteers with high levels of N. METHOD: Highly neurotic subjects received 20 mg/day citalopram versus placebo for 7 days in a double-blind, between-groups design. On the last day haemoperfusion and functional magnetic resonance imaging (fMRI) data during a gender discrimination task with fearful and happy faces were acquired. A control group of non-neurotic volunteers was also tested. RESULTS: High-N volunteers had reduced responses to threatening facial expressions across key neural circuits compared to low-N volunteers. SSRI treatment was found to elevate resting perfusion in the right amygdala, increase bilateral amygdalae activation to positive and negative facial expressions and increase activation to fearful versus happy facial expressions in occipital, parietal, temporal and prefrontal cortical areas. CONCLUSIONS: These results suggest that 7 days of SSRI administration can increase neural markers of fear reactivity in subjects at the high end of the N dimension and may be related to early increases in anxiety and agitation seen early in treatment. Such processes may be involved in the later therapeutic effects through decreased avoidance and increased learning about social 'threat' cues.
RCT Entities:
BACKGROUND: Short-term antidepressant administration has been reported to decrease amygdala response to threat in healthy volunteers and depressedpatients. Neuroticism (N) is a risk factor for depression but has also been associated with slow or incomplete remission with antidepressant drug treatment. Our aim was to investigate early selective serotonin reuptake inhibitor (SSRI) administration neural effects on implicit processing of fearful facial expressions in volunteers with high levels of N. METHOD: Highly neurotic subjects received 20 mg/day citalopram versus placebo for 7 days in a double-blind, between-groups design. On the last day haemoperfusion and functional magnetic resonance imaging (fMRI) data during a gender discrimination task with fearful and happy faces were acquired. A control group of non-neurotic volunteers was also tested. RESULTS: High-N volunteers had reduced responses to threatening facial expressions across key neural circuits compared to low-N volunteers. SSRI treatment was found to elevate resting perfusion in the right amygdala, increase bilateral amygdalae activation to positive and negative facial expressions and increase activation to fearful versus happy facial expressions in occipital, parietal, temporal and prefrontal cortical areas. CONCLUSIONS: These results suggest that 7 days of SSRI administration can increase neural markers of fear reactivity in subjects at the high end of the N dimension and may be related to early increases in anxiety and agitation seen early in treatment. Such processes may be involved in the later therapeutic effects through decreased avoidance and increased learning about social 'threat' cues.
Authors: Mary L Phillips; Henry W Chase; Yvette I Sheline; Amit Etkin; Jorge R C Almeida; Thilo Deckersbach; Madhukar H Trivedi Journal: Am J Psychiatry Date: 2015-02-01 Impact factor: 18.112
Authors: Duncan C Honeycutt; Melissa P DelBello; Jeffrey R Strawn; Laura B Ramsey; Luis R Patino; Kyle Hinman; Jeffrey Welge; David J Miklowitz; Booil Jo; Thomas J Blom; Kaitlyn M Bruns; Sarah K Hamill Skoch; Nicole Starace; Maxwell J Tallman; Manpreet K Singh Journal: J Pers Med Date: 2022-06-20
Authors: Andrea M Santangelo; Mitsuteru Ito; Yoshiro Shiba; Hannah F Clarke; Evelien Hs Schut; Gemma Cockcroft; Anne C Ferguson-Smith; Angela C Roberts Journal: Neuropsychopharmacology Date: 2016-03-21 Impact factor: 7.853
Authors: Azmeraw T Amare; Klaus Oliver Schubert; Fasil Tekola-Ayele; Yi-Hsiang Hsu; Katrin Sangkuhl; Gregory Jenkins; Ryan M Whaley; Poulami Barman; Anthony Batzler; Russ B Altman; Volker Arolt; Jürgen Brockmöller; Chia-Hui Chen; Katharina Domschke; Daniel K Hall-Flavin; Chen-Jee Hong; Ari Illi; Yuan Ji; Olli Kampman; Toshihiko Kinoshita; Esa Leinonen; Ying-Jay Liou; Taisei Mushiroda; Shinpei Nonen; Michelle K Skime; Liewei Wang; Masaki Kato; Yu-Li Liu; Verayuth Praphanphoj; Julia C Stingl; William V Bobo; Shih-Jen Tsai; Michiaki Kubo; Teri E Klein; Richard M Weinshilboum; Joanna M Biernacka; Bernhard T Baune Journal: Front Psychiatry Date: 2018-03-06 Impact factor: 4.157
Authors: Joey Ward; Nicholas Graham; Rona J Strawbridge; Amy Ferguson; Gregory Jenkins; Wenan Chen; Karen Hodgson; Mark Frye; Richard Weinshilboum; Rudolf Uher; Cathryn M Lewis; Joanna Biernacka; Daniel J Smith Journal: PLoS One Date: 2018-09-21 Impact factor: 3.240